Atypical medullary carcinoma of the breast has similar prognostic factors and survival to typical medullary breast carcinoma

3,976 cases from the National Cancer Data Base

Alina M. Mateo, Todd A. Pezzi, Mark Sundermeyer, Cynthia A. Kelley, Vicki Klimberg, Christopher M. Pezzi

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Backgrounds and Objectives: Medullary breast carcinoma (MBC) is a subtype with a more favorable prognosis. Tumors with some, but not all, characteristics of MBC are classified as atypical medullary carcinoma of the breast (AMCB). Methods: Patients with invasive MBC and AMCB reported to the National Cancer Data Base (NCDB) from 2004 to 2013 were compared for tumor characteristics and overall survival, using infiltrating ductal carcinoma (IDC) as a reference. Results: Patients with MBC (n = 3,688), AMCB (n = 288), and IDC (n = 918,870) met inclusion criteria. Comparing MBC with AMCB, the mean age at diagnosis (52.9 vs. 53.9 years), mean tumor size (2.4 vs. 2.5 cm), lymph node positivity (22.8% vs. 22.4%), estrogen receptor (ER) positivity (22% vs. 25%), progesterone receptor (PR) positivity (14% vs. 15%), HER2 positivity (11% vs. 14%), rate of breast conserving surgery (67% vs. 68%), use of chemotherapy (76% vs. 75%), and use of hormonal therapy (19% vs. 18%), respectively, were not clinically or statistically different. Five-year (92% vs. 89%) and 10-year survival rates (85% vs. 87%) were not significantly different (P = 0.46). Conclusions: There does not appear to be any reason to differentiate between AMCB and MBC given the similarities in presentation, treatment and prognosis. J. Surg. Oncol. 2016;114:533–536.

Original languageEnglish (US)
Pages (from-to)533-536
Number of pages4
JournalJournal of Surgical Oncology
Volume114
Issue number5
DOIs
StatePublished - Oct 1 2016
Externally publishedYes

Fingerprint

Medullary Carcinoma
Breast
Databases
Breast Neoplasms
Survival
Neoplasms
Ductal Carcinoma
Segmental Mastectomy
Progesterone Receptors
Estrogen Receptors
Survival Rate
Lymph Nodes

Keywords

  • atypical medullary breast cancer
  • medullary breast cancer
  • National Cancer Data Base

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Atypical medullary carcinoma of the breast has similar prognostic factors and survival to typical medullary breast carcinoma : 3,976 cases from the National Cancer Data Base. / Mateo, Alina M.; Pezzi, Todd A.; Sundermeyer, Mark; Kelley, Cynthia A.; Klimberg, Vicki; Pezzi, Christopher M.

In: Journal of Surgical Oncology, Vol. 114, No. 5, 01.10.2016, p. 533-536.

Research output: Contribution to journalArticle

@article{4f5ad319892b481cb6d22aff8c957b1a,
title = "Atypical medullary carcinoma of the breast has similar prognostic factors and survival to typical medullary breast carcinoma: 3,976 cases from the National Cancer Data Base",
abstract = "Backgrounds and Objectives: Medullary breast carcinoma (MBC) is a subtype with a more favorable prognosis. Tumors with some, but not all, characteristics of MBC are classified as atypical medullary carcinoma of the breast (AMCB). Methods: Patients with invasive MBC and AMCB reported to the National Cancer Data Base (NCDB) from 2004 to 2013 were compared for tumor characteristics and overall survival, using infiltrating ductal carcinoma (IDC) as a reference. Results: Patients with MBC (n = 3,688), AMCB (n = 288), and IDC (n = 918,870) met inclusion criteria. Comparing MBC with AMCB, the mean age at diagnosis (52.9 vs. 53.9 years), mean tumor size (2.4 vs. 2.5 cm), lymph node positivity (22.8{\%} vs. 22.4{\%}), estrogen receptor (ER) positivity (22{\%} vs. 25{\%}), progesterone receptor (PR) positivity (14{\%} vs. 15{\%}), HER2 positivity (11{\%} vs. 14{\%}), rate of breast conserving surgery (67{\%} vs. 68{\%}), use of chemotherapy (76{\%} vs. 75{\%}), and use of hormonal therapy (19{\%} vs. 18{\%}), respectively, were not clinically or statistically different. Five-year (92{\%} vs. 89{\%}) and 10-year survival rates (85{\%} vs. 87{\%}) were not significantly different (P = 0.46). Conclusions: There does not appear to be any reason to differentiate between AMCB and MBC given the similarities in presentation, treatment and prognosis. J. Surg. Oncol. 2016;114:533–536.",
keywords = "atypical medullary breast cancer, medullary breast cancer, National Cancer Data Base",
author = "Mateo, {Alina M.} and Pezzi, {Todd A.} and Mark Sundermeyer and Kelley, {Cynthia A.} and Vicki Klimberg and Pezzi, {Christopher M.}",
year = "2016",
month = "10",
day = "1",
doi = "10.1002/jso.24367",
language = "English (US)",
volume = "114",
pages = "533--536",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - Atypical medullary carcinoma of the breast has similar prognostic factors and survival to typical medullary breast carcinoma

T2 - 3,976 cases from the National Cancer Data Base

AU - Mateo, Alina M.

AU - Pezzi, Todd A.

AU - Sundermeyer, Mark

AU - Kelley, Cynthia A.

AU - Klimberg, Vicki

AU - Pezzi, Christopher M.

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Backgrounds and Objectives: Medullary breast carcinoma (MBC) is a subtype with a more favorable prognosis. Tumors with some, but not all, characteristics of MBC are classified as atypical medullary carcinoma of the breast (AMCB). Methods: Patients with invasive MBC and AMCB reported to the National Cancer Data Base (NCDB) from 2004 to 2013 were compared for tumor characteristics and overall survival, using infiltrating ductal carcinoma (IDC) as a reference. Results: Patients with MBC (n = 3,688), AMCB (n = 288), and IDC (n = 918,870) met inclusion criteria. Comparing MBC with AMCB, the mean age at diagnosis (52.9 vs. 53.9 years), mean tumor size (2.4 vs. 2.5 cm), lymph node positivity (22.8% vs. 22.4%), estrogen receptor (ER) positivity (22% vs. 25%), progesterone receptor (PR) positivity (14% vs. 15%), HER2 positivity (11% vs. 14%), rate of breast conserving surgery (67% vs. 68%), use of chemotherapy (76% vs. 75%), and use of hormonal therapy (19% vs. 18%), respectively, were not clinically or statistically different. Five-year (92% vs. 89%) and 10-year survival rates (85% vs. 87%) were not significantly different (P = 0.46). Conclusions: There does not appear to be any reason to differentiate between AMCB and MBC given the similarities in presentation, treatment and prognosis. J. Surg. Oncol. 2016;114:533–536.

AB - Backgrounds and Objectives: Medullary breast carcinoma (MBC) is a subtype with a more favorable prognosis. Tumors with some, but not all, characteristics of MBC are classified as atypical medullary carcinoma of the breast (AMCB). Methods: Patients with invasive MBC and AMCB reported to the National Cancer Data Base (NCDB) from 2004 to 2013 were compared for tumor characteristics and overall survival, using infiltrating ductal carcinoma (IDC) as a reference. Results: Patients with MBC (n = 3,688), AMCB (n = 288), and IDC (n = 918,870) met inclusion criteria. Comparing MBC with AMCB, the mean age at diagnosis (52.9 vs. 53.9 years), mean tumor size (2.4 vs. 2.5 cm), lymph node positivity (22.8% vs. 22.4%), estrogen receptor (ER) positivity (22% vs. 25%), progesterone receptor (PR) positivity (14% vs. 15%), HER2 positivity (11% vs. 14%), rate of breast conserving surgery (67% vs. 68%), use of chemotherapy (76% vs. 75%), and use of hormonal therapy (19% vs. 18%), respectively, were not clinically or statistically different. Five-year (92% vs. 89%) and 10-year survival rates (85% vs. 87%) were not significantly different (P = 0.46). Conclusions: There does not appear to be any reason to differentiate between AMCB and MBC given the similarities in presentation, treatment and prognosis. J. Surg. Oncol. 2016;114:533–536.

KW - atypical medullary breast cancer

KW - medullary breast cancer

KW - National Cancer Data Base

UR - http://www.scopus.com/inward/record.url?scp=84978209589&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978209589&partnerID=8YFLogxK

U2 - 10.1002/jso.24367

DO - 10.1002/jso.24367

M3 - Article

VL - 114

SP - 533

EP - 536

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 5

ER -